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Abstract
We examined the usefulness of five COVID-19 antibody detection tests using 114 serum
samples at various time points from 34 Japanese COVID-19 patients. We examined
Elecsys Anti-SARS-CoV-2 from Roche, and four immunochromatography tests from
Hangzhou Laihe Biotech, Artron Laboratories, Chil, and Nadal. In the first week after
onset, Elecsys had 40% positivity in Group S (severe cases) but was negative in Group M
(mild-moderate cases). The immunochromatography kits showed 40–60% and 0–8%
positivity in Groups S and M, respectively. In the second week, Elecsys showed 75% and
50% positivity, and the immunochromatography tests showed 5–80% and 50–75% posi-
tivity in Groups S and M, respectively. After the third week, Elecsys showed 100% positiv-
ity in both groups. The immunochromatography kits showed 100% positivity in Group S.
In Group M, positivity decreased to 50% for Chil and 75–89% for Artron and Lyher.
Elecsys and immunochromatography kits had 91–100% specificity. Elecsys had compa-
rable chronological change of cut-off index values in the two groups from the second
week to the sixth week. The current SARS-CoV-2 antibody detection tests do not provide
meaningful interpretation of severity and infection status. Its use might be limited to short-
term epidemiological studies.
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Introduction
The new coronavirus disease (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), originated from Wuhan, China in late 2019 and spread
worldwide. The World Health Organization (WHO) declared the pandemic on March 11,
2020. To control the pandemic, diagnostic tests such as reverse transcription polymerase
chain reaction (RT-PCR) methods were developed [1]. The results of these RT-PCR tests
were used for taking political decisions such as imposing lockdown in several countries [2,
3]. However, since RT-PCR tests are feasible only within three weeks since symptom onset,
it is inconvenient for epidemiological investigations. To estimate past infection numbers,
serological tests were developed (https://www.whitehouse.gov/wp-content/uploads/2020/
05/Testing-Guidance.pdf). As of January 2021, more than 33 serological tests are commer-
cially available as they were urgently approved by the United States Food and Drug Admin-
istration and European Medicines Agency. Importantly, more than 40 serological assays
were not approved (https://open.fda.gov/apis/device/covid19serology/), which suggests
that the performance of COVID-19 serological assays were not yet thoroughly investigated.
In addition, the significance of serological tests remains unclear as the Center for Disease
Control published interim guidelines for their use (https://www.cdc.gov/coronavirus/
2019-ncov/lab/resources/antibody-tests-guidelines.html).
SARS-CoV-2, a single-stranded RNA virus belonging to the Orthocoronavirinae subfamily,
consists of four structural components, namely, spike glycoprotein (S), envelope protein,
membrane glycoprotein, and nucleocapsid phosphoprotein (N), and 16 non-structural pro-
teins [4]. Thus, the accuracy and reliability of these tests rely upon the nucleotide fragments
used to develop the antibody. In addition, viral types may differ across infections at different
times. To date, at least 116 mutations including three common mutations have been identified
[5], and the seroprevalence timing might differ by viral type.
This study aimed to investigate the sensitivity, specificity, and time course of seroprevalence
in 34 Japanese COVID-19 patients using an electrochemiluminescence immunoassay
(ECLIA)-based Elecsys Anti-SARS-CoV-2 (RUO, Roche Diagnostics) test and four different
immunochromatographic (IC) point-of-care tests developed by Hangzhou Laihe Biotech,
Artron Laboratories, Chil, and Nadal.
Material and methods
Clinical backgrounds
This study complied with all relevant national regulations and institutional policies and was
conducted in accordance with the tenets of the Declaration of Helsinki. The study was
approved by the Institutional Review Board (IRB) at Juntendo University Hospital (IRB # 20–
036). The need for informed consent from individual patients was waived because all samples
were de-identified in line with the Declaration of Helsinki.
Between March and June 2020, 114 serum samples were collected from 34 COVID-19
patients. Table 1 shows the clinical characteristics and timing of sample collection. All patients
were confirmed to be positive according to PCR-based testing of SARS-CoV-2 using the Light
Mix Modular SARS-CoV-2 (COVID-19) N-gene and E-gene assay (Roche Diagnostics,
Tokyo, Japan) or the 2019 Novel Coronavirus Detection Kit (Shimadzu, Kyoto, Japan). We
classified patients into two groups according to the WHO criteria: Group M that included
mild and moderate cases and Group S that included severe and critical cases. For the negative
control, 100 serum samples collected from outpatients without infectious diseases between
November and December 2018 were used. The samples were stored at -80˚C until use. All data
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Antibody assays
We used the US Food and Drug Administration-approved Elecsys Anti-SARS-CoV-2 electro-
chemiluminescence immunoassay system (Roche Diagnostics, Basel, Switzerland), which is
based on the modified double-antigen sandwich immunoassay with recombinant nucleocapsid
protein (N) and measures SARS-CoV-2 total antibody (pan immunoglobulin) with a fully
automated Cobas e801 analyzer (Roche Diagnostics) (https://www.accessdata.fda.gov/cdrh_
docs/presentations/maf/maf3358-a001.pdf). According to the FDA, the Elecsys Anti-SARS--
CoV-2 system has 100% sensitivity (�14 days after a positive polymerase chain reaction [PCR]
assay) and 99.8% specificity (https://www.fda.gov/medical-devices/coronavirus-disease-
2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-
performance). The results are reported as numeric values in the form of a cutoff index (COI;
signal sample/cutoff) with qualitative results reactive (COI� 1.0; positive). The analytical and
clinical performance of the assay have been evaluated and are described elsewhere [6].
The following rapid immunochromatographic IgM/IgG antibody assays were utilized: LYHER
Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test (Hangzhou Laihe Biotech);
Artron COVID-19 IgM/IgG Antibody Test (Artron Laboratories); CHIL COVID-19 IgG/IgM
Rapid Test (Chil), and NADAL COVID-19 IgG/IgM test (nal von minden). The immunochroma-
tographic IgM/IgG antibody assays target the receptor binding domain of S protein or the nucleo-
capsid protein, N protein (Table 2). The presence of only the control line indicated a negative
result, whereas the presence of both the control line and the IgM or IgG antibody line indicated a
positive result for IgM or IgG antibody, respectively. Table 2 summarizes the features of these kits.
Statistics
Statistical analyses were performed using Stat Flex for Windows (ver. 6.0; Artech, Osaka,
Japan). The total Ig index between Group M and Group S was compared using the Mann-
Whitney U test. A two-tailed p value of<0.05 was considered statistically significant.
Table 1. Clinical characteristics.
Group M Group S�
Outpatients Inpatients Total
Patients number 16 10 26 8
Female, n (%) 5 (31.3) 4 (40.0) 9 (34.6) 1 (12.5)
Age, year 43 ± 18 51 ± 18 46 ± 18 70 ± 8
Sample number 16 45 61 53
0–6 days�� 12 0 12 5
7–13 days 4 4 8 8
14–20 days 0 13 13 10
21–27 days 0 7 7 7
28–34 days 0 8 8 10
35–41 days 0 9 9 7
42- 0 4 4 6
Data are expressed as mean±SD.
�All severe and critical cases were inpatients.
��Days from onset.
https://doi.org/10.1371/journal.pone.0246536.t001
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Results
Table 3 shows the sensitivity or the rate of positivity of Elecsys and the four immunochro-
matography kits in a total of 114 serum samples from 34 patients. The results of the immu-
nochromatography kits were considered as positive when IgM or IgG were positive
(qualitative tests).
In the first week after onset, Elecsys had a 40% positivity in Group S but was negative in
Group M. Additionally, the four immunochromatography kits had 40–60% and 0–8% positiv-
ity in the Groups S and M, respectively. In the second week, Elecsys showed 75% and 50% pos-
itivity in Groups S and M, respectively. The four immunochromatography kits had 63–88%
and 25–75% positivity in Groups S and M, respectively. After the third week, Elecsys showed
100% positivity in both groups, except for the fifth week in Group S (90%). Except for Chil, the
immunochromatography kits showed 100% positivity in Group S. In Group M, positivity
gradually decreased to 50% for Chil (IgM and IgG) and 75–89% for Artron and Lyher. Elecsys
and Nadal showed the most consistent positivity.
Specificity was evaluated using the samples collected before the COVID-19 era. Table 4
shows that the specificity of IgM was as low as 91% for Artron and 96% for Nadal. For IgG, all
kits showed a specificity of>98%.
Chronological change of COI
Next, we examined the COI values at various time points after onset using Elecsys. Fig 1 shows
that COI tended to increase over time. However, there was no significant difference between
Groups M and S until the sixth week. In the seventh week, the COI was higher in Group S
than in Group M.
To examine the chronological changes of COI in eight inpatients, the COI values were plot-
ted against the timing of the tests (Fig 2). Table 5 summarizes the patients’ clinical background
characteristics. Four patients (#1, 6, 7, and 8) required ventilation support, and unfortunately,
all patients could not be rescued. Three patients, except patient #1, showed relatively low
COIs. The COI of patient #1 reached 100 when the patient died at 52 days. In patient #6, the
COI did not increase at 13 days. Importantly, none of the deceased patients showed high COI
values on admission. The patients who survived (#2, 3, 4, and 5) received supplemental oxygen
and supporting therapies and were eventually discharged. Three of these (#2, 3, and 4) showed
relatively high COIs (around 40).
Table 2. Performance specification of reagent and kits.









Elecsys Anti-SARS-CoV-2 Roche Total Ig N 200 18 FDA (EUA), CE
Immnochromatography




IgM, IgG S-RBD 10 15 CE
Artron COVID-19 IgM/IgG Antibody Test Artron Laboratories IgM, IgG S-RBD 10 10 CE
Chil COVID-19 IgG/IgM Rapid Test Chil IgM, IgG S-RBD+N 5 15 CE
Nadal COVID-19 IgG/IgM Test nal von minden IgM, IgG S-RBD+N 10 15 CE
�S-RBD: Receptor Binding Domain of spike protein, N: Nucleocapsid.
��FDA (EUD): Food and Drug Administration (Emergency Use Authorization), CE: Conformite Europeenne.
https://doi.org/10.1371/journal.pone.0246536.t002
PLOS ONE COVID-19 antibody tests
PLOS ONE | https://doi.org/10.1371/journal.pone.0246536 February 8, 2021 4 / 10
Discussion
In this study, we evaluated the performance of five different SARS-CoV-2 antibody detection
tests using 114 serum samples from 34 Japanese patients with COVID-19 in a Tokyo
Table 4. Specificity of test kit.
Isotype Specificity (%) False positive (%)
Elecsys Anti-SARS-CoV-2 Total Ig 99 1
Artron COVID-19 IgM/IgG Antibody Test IgM 91 9
IgG 98 2
LYHER novel Coronavirus(2019-nCoV)IgM/IgG Antibody Combo Test IgM 99 1
IgG 99 1
CHIL COVID-19 IgG/IgM Rapid Test IgM 100 0
IgG 98 2
NADAL COVID-19 IgG/IgM Test IgM 96 4
IgG 99 1
https://doi.org/10.1371/journal.pone.0246536.t004
Table 3. Sensivity of SARS-CoV-2 antibody assay.
Elecsys (Total Ig)
Group M Group S
0–6 days 0 40
7–13 days 50 75
14–20 days 100 100
21–27 days 100 100
28–34 days 100 90
35–41 days 100 100
42- 100 100
Lyher Artron
Group M Group S Group M Group S
IgM IgG IgM/IgG IgM IgG IgM/IgG IgM IgG IgM/IgG IgM IgG IgM/IgG
0–6 days 8 0 8 60 40 60 8 0 8 60 40 60
7–13 days 50 25 50 75 63 75 63 13 63 75 63 75
14–20 days 100 85 100 100 100 100 100 85 100 100 100 100
21–27 days 100 100 100 100 100 100 100 100 100 100 100 100
28–34 days 100 75 100 100 100 100 100 75 100 100 100 100
35–41 days 100 89 100 100 100 100 100 89 100 100 100 100
42- 100 100 100 100 100 100 100 100 100 100 100 100
Chil Nadal
Group M Group S Group M Group S
IgM IgG IgM/IgG IgM IgG IgM/IgG IgM IgG Ig M/IgG IgM IgG IgM/IgG
0–6 days 8 8 8 60 60 60 8 8 8 60 60 60
7–13 days 50 50 50 50 88 88 50 50 63 63 75 63
14–20 days 92 92 100 80 100 100 100 100 100 100 100 100
21–27 days 100 100 100 100 100 100 100 100 100 100 100 100
28–34 days 88 88 100 100 100 100 100 100 100 100 100 100
35–41 days 56 56 89 86 100 100 100 100 100 100 100 100
42- 50 50 100 100 83 100 100 100 100 100 100 100
The data were presented as positive result percentage for tested numbers. IgM/IgG indicates positive for either IgM or IgG.
https://doi.org/10.1371/journal.pone.0246536.t003
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metropolitan area. Our study demonstrated several important findings. First, the seroprevalence
was approximately 40–60% in severe cases and relatively low in mild cases in the first week. The
seroprevalence increased to 60–80% in severe cases and 50–60% in mild cases in the second
week. After the third week, the seroprevalence reached almost 100% in both groups. In mild
cases, the seroprevalence decreased when tested with Artron and Chil kits (Table 3). Second, the
specificity was not 100% for all tests using the samples collected before the COVID-19 era
(Table 4). Third, the COI values using Elecsys did not differ significantly over time except for
the seventh week (Fig 1). However, this might be the effect of one outlier (patient #1 in Table 5).
In addition, the COI values obtained by Elecsys might not reflect disease severity (Fig 2).
It was reported that IgM and IgG could be detected in 20–30% of cases approximately 14
days after onset, and the positive rates reach 80–90% after 15 days [6]. Interestingly, it was
reported that IgM and IgG increased almost simultaneously [7]. In currently available antibody
detection kits, the antibodies were developed based on the S1 domain of the S protein or the N
protein. The N proteins are essential for viral survival and expansion, while the S proteins are
essential for binding to the host cell surface receptors [8]. Since the S proteins might be pro-
duced before the increase in the N proteins, the performance of antibody detection kits can
Fig 1. Seroprevalence of antibodies to SARS-CoV-2. Antibody Index for SARS-CoV-2 PCR-positive patient samples for the indicated weekly timeframes post-
onset of symptoms. The data were presented as mean with interquartile ranges. Open bars indicate Group M, and gray bars indicate Group S. Note that none of
Group M showed significant COI values in the first week. �p<0.05; NS, no significant difference.
https://doi.org/10.1371/journal.pone.0246536.g001
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depend upon the target protein of the antibody. This might explain why Chil and Artron kits
showed early decline of antibody levels in mild cases. However, how these kits were designed
are confidential. Another concern is the false-positive rate of Artron and Nadal kits. Since our
negative control samples were collected before 2018, antibodies against SARS-CoV-2 did not
Fig 2. Longitudinal changes of antibodies against SARS-CoV-2 in severe cases. The cut-off index in eight severe patients were tested using Elecsys. The COI
values were plotted as a function of days after onset. Closed symbols depict deceased cases, and open symbols depict survived cases.
https://doi.org/10.1371/journal.pone.0246536.g002
Table 5. Clinical characteristics of patients with Group S.
Patient # Severity� Outcome Age Sex Past medical history Treatments
1 Critical Deceased 76 M Hypertension Ventilation Continuous hemodiafiltration
Diabetes Plasmapheresis
Cancer
2 Severe Survived 77 M Diabetes Supplemental oxygen
Rheumatoid arthritis
Pneumonia
3 Severe Survived 75 M Prostatic hypertrophy Supplemental oxygen
4 Severe Survived 66 M none Supplemental oxygen
5 Severe Survived 57 M none Supplemental oxygen
6 Critical Deceased 78 F none Ventilation
7 Critical Deceased 64 F Hyperlipidemia Ventilation Continuous hemodiafiltration
Cancer Plasmapheresis
8 Critical Deceased 67 M Hypertension Ventilation Continuous hemodiafiltration
Renal failure Plasmapheresis
https://doi.org/10.1371/journal.pone.0246536.t005
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exist in these samples. Speculative explanations are antibody purification issues, difference in
the target fragments, and crossreaction with other coronaviruses including SARS and Middle
East Respiratory Syndrome (MERS).
Currently, SARS-CoV-2 is detected using RT-PCR, and it is believed that SARS-CoV-2
nucleotides can be detected using RT-PCR several days after symptom onset; however, the sen-
sitivity and specificity of this test are unclear [9]. After a certain time period (more than three
weeks), the sensitivity of PCR tests declines, and antibody tests may detect antibodies devel-
oped against nucleotide fragments of SARS-CoV-2. Currently, except for supporting therapies,
there is no available treatment option for COVID-19 despite several cases of experimental
drug use in the past several months [10–14]. Moreover, the pattern of seroprevalence remains
unclear. Although the sample number was small, the severe cases in our study did not show
any meaningful COI changes using Elecsys (Fig 2). In addition, our recent study showed that
seroprevalence in 4147 healthcare workers in our hospital was 0.34% [doi: 10.21203/rs.3.rs-
96870/v1]. Since the prevalence of COVID-19 is largely dependent on the number of PCR
tests in a given population [15], it is likely that the prevalence of COVID-19 has been underes-
timated. Therefore, this suggests that the antibodies detected by current methods might disap-
pear within a short period of time after infection [17].
Although many companies continue releasing new tests, we could test only limited num-
bers of assays commercially available in Japan when the study was performed. However, stud-
ies published in December 2020 have reported varying results in newer tests. Using 36 samples
obtained from RT-PCR confirmed COVID-19 patients, Sacristan et al. reported that the detec-
tion percentage of IgG antibodies were similar in StrongStep SARS-CoV-2 IgG/IgM kit and
AllTest COV-19 IgG/IgM kit (83.3%and 80.6%, respectively). In contrast, the IgM detection
rates were lower than the IgG detection rates, and different between the two tests (11.1% and
30.6%, respectively) [16]. The timing of the antibody tests was approximately 11 days after
RT-PCR tests, which is similar to our results between the second and the third week in Group
M. Nilsson et al. compared several assays using 98 samples collected at different time points
[17]. The assays included: EUROIMMUN anti-SARS-CoV-2 IgG and IgA ELISAs (EUROIM-
MUN Medizinische Labordiagnostika AG, Lübeck, Germany); WANTAI SARS-CoV-2 IgM
ELISA (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China); Acro IgM/IgG Lateral
Flow Test (LFT)(2019-nCoV IgG/IgM Rapid Test Cassette, Acro Biotech, Rancho Cucamonga,
CA, USA); Livzon IgM/IgG LFT (Diagnostic Kit for IgM/IgG Antibody to Corona Virus, Zhu-
hai Livzon Diagnostics, Zhuhai, China); and CTK IgM/IgG LFT (OnSiteTM COVID-19 IgG/
IgM Rapid Test, CTK Biotech, Poway, CA). According to their results, WANTAI ELISA and
Acro LFT were more sensitive than others in detecting IgM antibodies in the first week after
onset. However, the sample size was small, consisting of only three patients. WANTAI ELISA
and CTK LFT showed higher positivity for IgM between 8 and 28 days, then declined after 28
days. For the IgG antibody detections, all tests showed low sensitivity in the first week. Acro
LFT showed a positivity of 91–100% between 8 and 28 days, which was better than the other
assays. The other tests showed 57–94% positivity between 8–28 days, then declined after 28
days. They also compared the positivity among the outpatients, hospitalized and ICU admitted
patients. All tests tended to show higher positivity in the inpatients compared to the outpa-
tients, which is consistent with our data (Table 3). However, the positivity varied depending
upon the assay. In addition, a meta-analysis of 57 studies published in June 2020 reported the
low sensitivity and high heterogeneity of the serological tests [18]. All these results indicate
unreliability and difficulty in developing serological tests against SARS-CoV-2, a single strand
RNA virus even with slower mutation rates than other RNA viruses [19, 20]. Furthermore,
there are many confounding factors such as difference in methodology, antibody development,
and uncertainty of pathogens.
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This study has several limitations: (1) this is a single-center study with a relatively small
number of patients; (2) since the target nucleotides to develop antibodies are not disclosed,
data interpretation was incomplete; (3) since the follow-up time was limited to 42 days, we do
not know the long-term detection rate; (4) finally, we do not know whether these antibodies
act as neutral antibodies.
In conclusion, our data showed that the serological tests including one ECLIA test and four
immunochromatography tests had poor sensitivity during the early phase of infection and
therefore were unsuitable for diagnosis or screening. In addition, these tests cannot provide
meaningful interpretation of infection status. Thus, the current use of these tests might be lim-
ited to short-term epidemiological studies unless newer and more reliable technologies are
developed in the future.
Acknowledgments
The authors are grateful to the participants in this study. The authors also would like to thank
Natsumi Itakura, Masayoshi Chonan, Koji Tsuchiya and Takaaki Kawakami for their technical
supports, and Dr. Corina Rosales for critical reading manuscript. Finally, we thank to all medi-
cal staff who conducted their duties in the treatment of this pandemic.
Author Contributions
Conceptualization: Yoko Tabe.
Data curation: Mitsuru Wakita, Mayumi Idei, Kaori Saito, Yuki Horiuchi, Kotoko Yamatani,
Suzuka Ishikawa, Takamasa Yamamoto, Gene Igawa, Masanobu Hinata, Katsuhiko Kadota,
Taro Kurosawa, Sho Takahashi, Takumi Saito.
Formal analysis: Mitsuru Wakita, Mayumi Idei, Kaori Saito, Yuki Horiuchi, Kotoko Yama-
tani, Suzuka Ishikawa, Takamasa Yamamoto, Gene Igawa, Masanobu Hinata, Katsuhiko
Kadota, Taro Kurosawa, Sho Takahashi, Takumi Saito, Chihiro Akazawa, Tomohiko Ai.
Investigation: Suzuka Ishikawa, Katsuhiko Kadota, Taro Kurosawa, Sho Takahashi, Takumi
Saito, Shigeki Misawa, Chihiro Akazawa, Toshio Naito.
Project administration: Shigeki Misawa, Toshio Naito, Yoko Tabe.
Supervision: Shigeki Misawa, Chihiro Akazawa, Toshio Naito, Takashi Miida, Kazuhisa Taka-
hashi, Yoko Tabe.
Validation: Shigeki Misawa, Chihiro Akazawa, Toshio Naito, Takashi Miida, Kazuhisa Taka-
hashi, Tomohiko Ai, Yoko Tabe.
Writing – original draft: Mayumi Idei, Yuki Horiuchi, Kotoko Yamatani, Takamasa Yama-
moto, Gene Igawa, Masanobu Hinata, Tomohiko Ai.
Writing – review & editing: Tomohiko Ai, Yoko Tabe.
References
1. Benzigar MR, Bhattacharjee R, Baharfar M, Liu G. Current methods for diagnosis of human coronavi-
ruses: pros and cons. Anal Bioanal Chem. 2020. Epub 2020/11/22. https://doi.org/10.1007/s00216-
020-03046-0 PMID: 33219449; PubMed Central PMCID: PMC7679240.
2. Mattern J, Vauloup-Fellous C, Zakaria H, Benachi A, Carrara J, Letourneau A, et al. Post lockdown
COVID-19 seroprevalence and circulation at the time of delivery, France. PLoS One. 2020; 15(10):
e0240782. Epub 2020/10/16. https://doi.org/10.1371/journal.pone.0240782 PMID: 33057392; PubMed
Central PMCID: PMC7561105.
PLOS ONE COVID-19 antibody tests
PLOS ONE | https://doi.org/10.1371/journal.pone.0246536 February 8, 2021 9 / 10
3. Pachetti M, Marini B, Giudici F, Benedetti F, Angeletti S, Ciccozzi M, et al. Impact of lockdown on
Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America. J
Transl Med. 2020; 18(1):338. Epub 2020/09/04. https://doi.org/10.1186/s12967-020-02501-x PMID:
32878627; PubMed Central PMCID: PMC7463225.
4. Satarker S, Nampoothiri M. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2.
Arch Med Res. 2020; 51(6):482–91. Epub 2020/06/05. https://doi.org/10.1016/j.arcmed.2020.05.012
PMID: 32493627; PubMed Central PMCID: PMC7247499.
5. Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep.
2020; 19:100682. Epub 2020/04/18. https://doi.org/10.1016/j.genrep.2020.100682 PMID: 32300673;
PubMed Central PMCID: PMC7161481.
6. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of
novel coronavirus disease 2019. Clin Infect Dis. 2020. Epub 2020/03/30. https://doi.org/10.1093/cid/
ciaa344 PMID: 32221519; PubMed Central PMCID: PMC7184337.
7. Mazzini L, Martinuzzi D, Hyseni I, Benincasa L, Molesti E, Casa E, et al. Comparative analyses of
SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immu-
nol Methods. 2020:112937. Epub 2020/12/01. https://doi.org/10.1016/j.jim.2020.112937 PMID:
33253698; PubMed Central PMCID: PMC7695554.
8. Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, et al. Crystal structure of SARS-CoV-2 nucleo-
capsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B.
2020; 10(7):1228–38. Epub 2020/05/05. https://doi.org/10.1016/j.apsb.2020.04.009 PMID: 32363136;
PubMed Central PMCID: PMC7194921.
9. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in
relation to COVID-19 severity. J Clin Invest. 2020; 130(10):5235–44. Epub 2020/07/08. https://doi.org/
10.1172/JCI138759 PMID: 32634129; PubMed Central PMCID: PMC7524490.
10. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with
or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020; 383(21):2041–52. Epub 2020/
07/25. https://doi.org/10.1056/NEJMoa2019014 PMID: 32706953; PubMed Central PMCID: PMC7397242.
11. McCartney M. COVID-19: has EBM been replaced by hype-based medicine? Drug Ther Bull. 2020; 58
(7):99–100. Epub 2020/05/27. https://doi.org/10.1136/dtb.2020.000029 PMID: 32451323.
12. Farnsworth CW, Anderson NW. SARS-CoV-2 Serology: Much Hype, Little Data. Clin Chem. 2020; 66
(7):875–7. Epub 2020/04/29. https://doi.org/10.1093/clinchem/hvaa107 PMID: 32343775; PubMed
Central PMCID: PMC7197624.
13. Alhumaid S, Mutair AA, Alawi ZA, Alhmeed N, Zaidi ARZ, Tobaiqy M. Efficacy and Safety of Lopinavir/
Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. Trop Med Infect Dis.
2020; 5(4). Epub 2020/12/03. https://doi.org/10.3390/tropicalmed5040180 PMID: 33260553.
14. Emani VR, Goswami S, Nandanoor D, Emani SR, Reddy NK, Reddy R. Randomised controlled trials
for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the com-
pleted trials and to improve ongoing and future randomised trial designs. Int J Antimicrob Agents.
2020:106222. Epub 2020/11/16. https://doi.org/10.1016/j.ijantimicag.2020.106222 PMID: 33189891;
PubMed Central PMCID: PMC7659806.
15. Wu SL, Mertens AN, Crider YS, Nguyen A, Pokpongkiat NN, Djajadi S, et al. Substantial underestimation
of SARS-CoV-2 infection in the United States. Nat Commun. 2020; 11(1):4507. Epub 2020/09/11.
https://doi.org/10.1038/s41467-020-18272-4 PMID: 32908126; PubMed Central PMCID: PMC7481226.
16. Sacristan MS, Collazos-Blanco A, Cintas MIZ, Garcia AS, de Villavicencio CY, Maestre MM. Compari-
son of various serological assays for novel SARS-COV-2. Eur J Clin Microbiol Infect Dis. 2020. Epub
2020/11/26. https://doi.org/10.1007/s10096-020-04091-4 PMID: 33236270; PubMed Central PMCID:
PMC7685776.
17. Nilsson AC, Holm DK, Justesen US, Gorm-Jensen T, Andersen NS, Ovrehus A, et al. Comparison of
six commercially available SARS-CoV-2 antibody assays-Choice of assay depends on intended use.
Int J Infect Dis. 2020; 103:381–8. Epub 2020/12/15. https://doi.org/10.1016/j.ijid.2020.12.017 PMID:
33310021; PubMed Central PMCID: PMC7726521.
18. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for
identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020; 6:
CD013652. Epub 2020/06/26. https://doi.org/10.1002/14651858.CD013652 PMID: 32584464; PubMed
Central PMCID: PMC7387103.
19. Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018; 16(8):e3000003. Epub
2018/08/14. https://doi.org/10.1371/journal.pbio.3000003 PMID: 30102691; PubMed Central PMCID:
PMC6107253.
20. Callaway E. The coronavirus is mutating—does it matter? Nature. 2020; 585(7824):174–7. Epub 2020/
09/10. https://doi.org/10.1038/d41586-020-02544-6 PMID: 32901123.
PLOS ONE COVID-19 antibody tests
PLOS ONE | https://doi.org/10.1371/journal.pone.0246536 February 8, 2021 10 / 10
